Olaparib
| Evidence Level: N/A | Predicted Indications: 0 |
Table of Contents
- Olaparib
Olaparib: Known uses and market status in Canada
Summary
The TxGNN deep-learning model (score ≥ 0.99) produced candidate indications for Olaparib. Every candidate that can be traced to a source is already a known use, so there is currently no new predicted indication. The one known use is in the same disease category as an approved indication.
Quick overview
| Item | Content |
|---|---|
| New predicted indications | None (all traceable model candidates are known uses) |
| Known uses among model candidates | 1 |
| Evidence level | Not applicable |
| Canada Market Status | Marketed (marketed DINs: 2 of 2) |
| Number of DINs | 2 (marketed: 2) |
Known uses among the model’s candidates
Approved (supported by a licence or label)
| Indication | Source |
|---|---|
| none | none |
Related to an approved indication (same disease category)
| Indication | Approved category |
|---|---|
| female breast carcinoma | breast cancer |
Relations recorded in the knowledge graph (no approval found)
| Indication |
|---|
| none |
Canada Market Information
| Licence | Product | Dosage form | Status |
|---|---|---|---|
| 02475200 | LYNPARZA | Valid | |
| 02475219 | LYNPARZA | Valid |
Cytotoxicity
| Item | Content |
|---|---|
| Cytotoxicity Classification | Targeted therapy (PARP inhibitor) |
| Myelosuppression Risk | Medium; anaemia, neutropenia and thrombocytopenia are recognised with PARP inhibitors, so blood counts should be monitored |
| Emetogenicity Classification | Low to medium |
| Monitoring Items | CBC (with differential), liver and renal function |
| Handling Protection | Please refer to the package insert warnings and precautions |
Safety Considerations
- Drug Interactions: The interaction screening returned 100 interacting drugs. The most clinically important are those rated Major: aprepitant, dexamethasone and clarithromycin. These are likely related to CYP3A-mediated metabolism, so concomitant use needs review. Many others are rated Moderate, including metformin, bupropion, cimetidine, miconazole, clotrimazole, glyburide, ondansetron, repaglinide, rosuvastatin and simvastatin. Prucalopride is rated Minor.
For other safety information, such as warnings and contraindications, please refer to the package insert.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.